TW202308616A - 用於增加紅血球及/或血紅素之組成物 - Google Patents

用於增加紅血球及/或血紅素之組成物 Download PDF

Info

Publication number
TW202308616A
TW202308616A TW111115162A TW111115162A TW202308616A TW 202308616 A TW202308616 A TW 202308616A TW 111115162 A TW111115162 A TW 111115162A TW 111115162 A TW111115162 A TW 111115162A TW 202308616 A TW202308616 A TW 202308616A
Authority
TW
Taiwan
Prior art keywords
composition
ergothioneine
salt
hemoglobin
present
Prior art date
Application number
TW111115162A
Other languages
English (en)
Chinese (zh)
Inventor
勝部諒
渡辺斉志
村山宣人
Original Assignee
日商三得利控股股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商三得利控股股份有限公司 filed Critical 日商三得利控股股份有限公司
Publication of TW202308616A publication Critical patent/TW202308616A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111115162A 2021-04-26 2022-04-21 用於增加紅血球及/或血紅素之組成物 TW202308616A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021074320 2021-04-26
JP2021-074320 2021-04-26

Publications (1)

Publication Number Publication Date
TW202308616A true TW202308616A (zh) 2023-03-01

Family

ID=83847365

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111115162A TW202308616A (zh) 2021-04-26 2022-04-21 用於增加紅血球及/或血紅素之組成物

Country Status (7)

Country Link
US (1) US20240180876A1 (cg-RX-API-DMAC7.html)
EP (1) EP4331580A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022230487A1 (cg-RX-API-DMAC7.html)
CN (1) CN117202904A (cg-RX-API-DMAC7.html)
AU (1) AU2022267109A1 (cg-RX-API-DMAC7.html)
TW (1) TW202308616A (cg-RX-API-DMAC7.html)
WO (1) WO2022230487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4052704A4 (en) * 2019-10-28 2023-12-13 Suntory Holdings Limited Composition for sleep improvement comprising ergothioneine or salt thereof
AU2022392070A1 (en) * 2021-11-17 2024-05-02 Suntory Holdings Limited Composition for inhibiting histamine-n-methyltransferase
WO2024038821A1 (ja) * 2022-08-17 2024-02-22 サントリーホールディングス株式会社 フレイル予防又は改善用組成物、及び、加齢に伴う身体活動能力低下を抑制又は改善するための組成物
WO2025157153A1 (zh) * 2024-01-25 2025-07-31 南京纽邦生物科技有限公司 用于增强运动表现的方法及组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
JP5658479B2 (ja) 2009-04-27 2015-01-28 株式会社岩出菌学研究所 脂肪減少等の活性を示す組成物
US20140121156A1 (en) * 2011-06-13 2014-05-01 Entia Biosciences, Inc. Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine
CA2877861A1 (en) * 2012-06-26 2014-01-03 Entia Biosciences, Inc. A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2
JP5904378B2 (ja) * 2013-02-28 2016-04-13 株式会社エル・エスコーポレーション 抗うつ剤
WO2020004014A1 (ja) * 2018-06-29 2020-01-02 長瀬産業株式会社 エルゴチオネイン、アスコルビン酸2-グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Also Published As

Publication number Publication date
JPWO2022230487A1 (cg-RX-API-DMAC7.html) 2022-11-03
AU2022267109A1 (en) 2023-10-12
EP4331580A4 (en) 2025-03-19
US20240180876A1 (en) 2024-06-06
EP4331580A1 (en) 2024-03-06
CN117202904A (zh) 2023-12-08
WO2022230487A1 (ja) 2022-11-03

Similar Documents

Publication Publication Date Title
US20240180876A1 (en) Composition for increasing red blood cells and/or hemoglobin
JP7764471B2 (ja) 腎機能の低下抑制又は改善用組成物
JP7757450B2 (ja) エルゴチオネイン又はその塩を含有する睡眠改善用組成物
JP7796116B2 (ja) 抗不安用組成物
TW202423421A (zh) 預防或改善衰弱用之組成物,及抑制或改善高齡所伴隨之身體活動力降低用之組成物
US20240189284A1 (en) Composition for promoting lipolysis
JP7796117B2 (ja) 血中コレステロール値改善用組成物
HK40103316A (en) Composition for increasing red blood cells and/or hemoglobin
CN121001582A (zh) 含有麦角硫因或其盐的用于预防、减轻或改善中暑或脱水症的组合物及用于调节细胞内外水分的组合物
WO2024172002A1 (ja) エルゴチオネインを含有する血管拡張用組成物
HK40129889A (zh) 含有麦角硫因的血管扩张用组合物
HK40103317A (en) Composition for ameliorating or suppressing decline of kidney functions
TW202448445A (zh) 含有麥角硫因之肌肉萎縮抑制用組成物及Src酪胺酸激酶阻礙用組成物
HK40104490A (en) Composition for promoting lipolysis
HK40129887A (zh) 含有麦角硫因的肌肉萎缩抑制用组合物及src酪氨酸激酶阻碍用组合物
HK40075030A (en) Composition for sleep improvement comprising ergothioneine or salt thereof
HK40104913A (en) Anti-anxiety composition